FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166545910> ?p ?o ?g. }

• W2166545910 endingPage "458" @default.
• W2166545910 startingPage "453" @default.
• W2166545910 abstract "Background: Myelotoxicity, a major toxicity of vinorelbine, may be related to the degree of one's exposure to vinorelbine. In theory, clarithromycin has the potential to alter vinorelbine's pharmacokinetics by inhibiting CYP3A and/or P-glycoprotein; this may result in massive exposure to vinorelbine and severe toxicity. To date, macrolide–vinorelbine drug interactions have not been reported. Objective: To estimate the clinical risk of a interaction between vinorelbine and clarithromycin. Methods: In a retrospective cohort study, we searched computerized medical records of patients who had been administered vinorelbine in the University of Fukui Hospital. The study cohort was defined as all patients with non–small-cell lung cancer who received vinorelbine between May 30, 2003, and January 31, 2008. The treatment courses were classified according to whether or not clarithromycin was concomitantly administered with vinorelbine. Nadir neutrophil counts were recorded as the major outcomes. Vinorelbine–clarithromycin interaction was defined as a significant increase in the risk of severe neutropenia when the 2 drugs were administered concomitantly. Results: A total of 12 (63.2%) and 11 (27.5%) episodes of grade 3/4 neutropenia occurred among the patients who were and were not administered clarithromycin, respectively. The incidence of grade 4 neutropenia was higher in the group administered clarithromycin than in those who did not receive it (31.6% vs 2.5%; p = 0.0033). Vinorelbine dose, concomitant clarithromycin administration, and female sex were significantly correlated with severe neutropenia, with unadjusted odds ratios of 0.07 (95% CI 0.01 to 0.59), 4.52 (95% CI 1.41 to 14.45), and 4.55 (95% CI 1.39 to 14.29), respectively. Conclusions: Compared with patients who are administered vinorelbine alone, patients who are administered clarithromycin during chemotherapy with vinorelbine are at a higher risk for severe neutropenia. Physicians should educate their patients about this interaction. If possible, clarithromycin administration should be avoided in patients who will undergo chemotherapy with vinorelbine in the near future. However, further prospective pharmacokinetic studies are required to confirm this interaction." @default.
• W2166545910 created "2016-06-24" @default.
• W2166545910 creator A5007409101 @default.
• W2166545910 creator A5011616123 @default.
• W2166545910 creator A5020680556 @default.
• W2166545910 creator A5034233408 @default.
• W2166545910 creator A5035824103 @default.
• W2166545910 creator A5054797135 @default.
• W2166545910 creator A5080871072 @default.
• W2166545910 date "2009-03-01" @default.
• W2166545910 modified "2023-09-24" @default.
• W2166545910 title "Evaluation of Potential Interaction Between Vinorelbine and Clarithromycin" @default.
• W2166545910 cites W1178002584 @default.
• W2166545910 cites W1531474084 @default.
• W2166545910 cites W1641696410 @default.
• W2166545910 cites W1978599196 @default.
• W2166545910 cites W1997520975 @default.
• W2166545910 cites W2011863821 @default.
• W2166545910 cites W2020449031 @default.
• W2166545910 cites W2030204704 @default.
• W2166545910 cites W2043249607 @default.
• W2166545910 cites W2043460726 @default.
• W2166545910 cites W2045232700 @default.
• W2166545910 cites W2049844577 @default.
• W2166545910 cites W2062699124 @default.
• W2166545910 cites W2066178728 @default.
• W2166545910 cites W2076946520 @default.
• W2166545910 cites W2081159160 @default.
• W2166545910 cites W2097877048 @default.
• W2166545910 cites W2112776466 @default.
• W2166545910 cites W2121823208 @default.
• W2166545910 cites W2122431144 @default.
• W2166545910 cites W2129793485 @default.
• W2166545910 cites W2133176934 @default.
• W2166545910 cites W2137009016 @default.
• W2166545910 cites W2151522757 @default.
• W2166545910 cites W2152558468 @default.
• W2166545910 cites W2153267334 @default.
• W2166545910 cites W2157075977 @default.
• W2166545910 cites W2157184495 @default.
• W2166545910 cites W2607182122 @default.
• W2166545910 doi "https://doi.org/10.1345/aph.1l432" @default.
• W2166545910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19261952" @default.
• W2166545910 hasPublicationYear "2009" @default.
• W2166545910 type Work @default.
• W2166545910 sameAs 2166545910 @default.
• W2166545910 citedByCount "16" @default.
• W2166545910 countsByYear W21665459102012 @default.
• W2166545910 countsByYear W21665459102013 @default.
• W2166545910 countsByYear W21665459102014 @default.
• W2166545910 countsByYear W21665459102017 @default.
• W2166545910 countsByYear W21665459102018 @default.
• W2166545910 countsByYear W21665459102019 @default.
• W2166545910 countsByYear W21665459102020 @default.
• W2166545910 countsByYear W21665459102023 @default.
• W2166545910 crossrefType "journal-article" @default.
• W2166545910 hasAuthorship W2166545910A5007409101 @default.
• W2166545910 hasAuthorship W2166545910A5011616123 @default.
• W2166545910 hasAuthorship W2166545910A5020680556 @default.
• W2166545910 hasAuthorship W2166545910A5034233408 @default.
• W2166545910 hasAuthorship W2166545910A5035824103 @default.
• W2166545910 hasAuthorship W2166545910A5054797135 @default.
• W2166545910 hasAuthorship W2166545910A5080871072 @default.
• W2166545910 hasConcept C126322002 @default.
• W2166545910 hasConcept C143998085 @default.
• W2166545910 hasConcept C2776409635 @default.
• W2166545910 hasConcept C2776694085 @default.
• W2166545910 hasConcept C2776962512 @default.
• W2166545910 hasConcept C2777063308 @default.
• W2166545910 hasConcept C2778239845 @default.
• W2166545910 hasConcept C2780350996 @default.
• W2166545910 hasConcept C71924100 @default.
• W2166545910 hasConceptScore W2166545910C126322002 @default.
• W2166545910 hasConceptScore W2166545910C143998085 @default.
• W2166545910 hasConceptScore W2166545910C2776409635 @default.
• W2166545910 hasConceptScore W2166545910C2776694085 @default.
• W2166545910 hasConceptScore W2166545910C2776962512 @default.
• W2166545910 hasConceptScore W2166545910C2777063308 @default.
• W2166545910 hasConceptScore W2166545910C2778239845 @default.
• W2166545910 hasConceptScore W2166545910C2780350996 @default.
• W2166545910 hasConceptScore W2166545910C71924100 @default.
• W2166545910 hasIssue "3" @default.
• W2166545910 hasLocation W21665459101 @default.
• W2166545910 hasLocation W21665459102 @default.
• W2166545910 hasOpenAccess W2166545910 @default.
• W2166545910 hasPrimaryLocation W21665459101 @default.
• W2166545910 hasRelatedWork W1967254937 @default.
• W2166545910 hasRelatedWork W1969040638 @default.
• W2166545910 hasRelatedWork W1997053705 @default.
• W2166545910 hasRelatedWork W2011790448 @default.
• W2166545910 hasRelatedWork W2045264832 @default.
• W2166545910 hasRelatedWork W2103690872 @default.
• W2166545910 hasRelatedWork W2136438932 @default.
• W2166545910 hasRelatedWork W2156787342 @default.
• W2166545910 hasRelatedWork W2410374637 @default.
• W2166545910 hasRelatedWork W2993131327 @default.
• W2166545910 hasVolume "43" @default.
• W2166545910 isParatext "false" @default.

• next